Copy
See below for a daily digest of the latest Huntington's Disease news!

Huntington's Disease News Weekly Digest

Contents:

Phase 2a Trial Investigates BP Medicine SOM3355 as Treatment for Chorea

Jul 25, 2018 03:30 pm | Alice Melão

 

SOM3355 Phase 2a trialSOM3355 — a medicine approved for high blood pressure and chest pain — is being tested in a Phase 2 trial as a means to treat chorea in Huntington’s disease patients, SOM Biotech announced. The proof-of-concept study (NCT03575676) will recruit participants in four clinical sites in or near Barcelona, Spain. It is expected to include about 30 patients with […]

The post Phase 2a Trial Investigates BP Medicine SOM3355 as Treatment for Chorea appeared first on Huntington's Disease News.

Read More
share on Twitter Like Phase 2a Trial Investigates BP Medicine SOM3355 as Treatment for Chorea on Facebook

Recent Posts

Genes Involved in Inflammation, Cellular Structure May Be Therapeutic Targets in Huntington’s
Retrotope’s RT001 Reduced Cognitive Defects in Mice with Huntington’s Disease, Study Shows
Improved Genetic Testing Protocols Should be Available for Huntington’s Disease, Study Contends
Skyhawk, Celgene Partner to Develop Small Molecule Treatments for Huntington’s, Other Neurological Diseases
Scotland’s Fife Launches Groundbreaking Local Care Frameworks for Huntington’s Disease

Copyright © 2018 BioNews Services, LLC, All rights reserved.
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences